Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Beigene Ltd ADR (BGNE)

Beigene Ltd ADR (BGNE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Insider Sale: Director at $BGNE (BGNE) Sells 916,964 Shares Quiver Quantitative, Inc. - Wed Dec 11, 6:42AM CST

BROS. ADVISORS LP BAKER, a director at $BGNE ($BGNE), sold 916,964 shares of the company on 12-09-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 9.5% of...

BGNE : 176.50 (+1.02%)
Insider Sale: Director at $BGNE (BGNE) Sells 200 Shares Quiver Quantitative, Inc. - Sat Nov 30, 1:52AM CST

Xiaodong Wang, a director at $BGNE ($BGNE), sold 200 shares of the company on 11-26-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 0.7% of their shares....

BGNE : 176.50 (+1.02%)
BeiGene Stock Eyes 2-Week High After EU Approves Cancer Treatment: Retail Enthusiasm Grows Stocktwits - Wed Nov 27, 6:58AM CST

The latest approval adds to BeiGene’s momentum, marking six EU indications granted in just over a year.

BGNE : 176.50 (+1.02%)
FBT : 165.53 (+0.92%)
BIB : 51.41 (+1.80%)
QQQJ : 31.36 (+1.39%)
Active Biotech Alert: FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket FinancialNewsMedia - Fri Oct 4, 8:15AM CDT

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:ABBV),(NASDAQ:BGNE),(NASDAQ:HCM),(NASDAQ:ELVN) EQNX::TICKER_END

ONCY : 0.8310 (-6.36%)
BGNE : 176.50 (+1.02%)
HCM : 14.31 (-2.05%)
ABBV : 175.58 (+2.37%)
ONC.TO : 1.19 (-9.16%)
ELVN : 22.47 (-1.75%)
FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket Newswire.ca - Fri Oct 4, 8:00AM CDT

/CNW/ -- USA News Group News Commentary – While some forms of cancer are seeing death rates fall, the world is witnessing a global surge in cancers among...

ONCY : 0.8310 (-6.36%)
BGNE : 176.50 (+1.02%)
HCM : 14.31 (-2.05%)
ABBV : 175.58 (+2.37%)
ONC.TO : 1.19 (-9.16%)
ELVN : 22.47 (-1.75%)
Investors Watch Key Players in Oncology as Cancer Cases Set to Skyrocket BayStreet.ca - Fri Sep 20, 10:07AM CDT

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group – The surge in...

ONCY : 0.8310 (-6.36%)
BGNE : 176.50 (+1.02%)
EXEL : 33.29 (-1.16%)
ABBV : 175.58 (+2.37%)
ONC.TO : 1.19 (-9.16%)
AMGN : 263.38 (+0.84%)
Healthcare (names I - Z) - Regeneron Pharmaceuticals, Inc_ logo on phone-by Piotr Swat via Shutterstock
Is Regeneron Pharmaceuticals Stock Outperforming the S&P 500? Barchart - Wed Sep 4, 2:49AM CDT

Regeneron Pharmaceuticals has outperformed the broader S&P 500 Index over the past year, and Wall Street analysts remain bullish on the stock’s prospects.

REGN : 701.85 (-0.90%)
$SPX : 5,930.85 (+1.09%)
$SPX : 5,930.85 (+1.09%)
BGNE : 176.50 (+1.02%)
AbbVie Could Soar 24%, According to a Wall Street Analyst. Is the High-Yield Dividend Stock a Buy Now? Motley Fool - Mon Jul 22, 9:41AM CDT

The big pharma company's top drug is losing ground, but its dividend keeps rising.

CVS : 44.36 (+1.32%)
UNH : 500.13 (+2.22%)
ABT : 114.23 (+1.61%)
CI : 276.92 (+0.77%)
AZN : 65.35 (+1.41%)
BGNE : 176.50 (+1.02%)
RVNC : 3.09 (+0.65%)
ABBV : 175.58 (+2.37%)
Health Canada Approves BRUKINSA® (zanubrutinib) for the Treatment of Relapsed or Refractory Follicular Lymphoma Newswire.ca - Wed Feb 7, 5:47AM CST

/CNW/ - BeiGene, Ltd. (Nasdaq: BGNE) (HKEX: 06160) (SSE: 688235), a global biotechnology company, today announced it received Health Canada authorization for...

BGNE : 176.50 (+1.02%)
Adults living with chronic lymphocytic leukemia (CLL) in Ontario and Quebec now have access, through public reimbursement, to BRUKINSA® (zanubrutinib) Newswire.ca - Wed Jan 31, 5:47AM CST

/CNW/ - BeiGene, Ltd. (NASDAQ: BGNE) (HKEX: 06160) (SSE: 688235), a global biotechnology company is pleased to announce that the Governments of Ontario and...

BGNE : 176.50 (+1.02%)

Barchart Exclusives

Oracle Stock Is Off Its Highs and Could Be Cheap Here Barchart - Sun Dec 22, 9:30AM CST
Oracle Corp. produced higher revenue in Q2 but lower free cash flow and FCF margins. However, ORCL stock is now off its highs and could be undervalued here. Shorting out-of-the-money puts is one way to play it. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot